Critical

Invasive pulmonary aspergillosis

IPA · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Invasive aspergillosis is an angioinvasive mould infection mainly affecting neutropenic and other immunocompromised hosts, typically pulmonary. Early voriconazole/isavuconazole and reduction of immunosuppression are crucial; mortality is high.

Red flags

  • Massive haemoptysis (vessel erosion)
  • Rapidly progressive hypoxia
  • Dissemination (cerebral aspergillosis)
  • Breakthrough infection on azole prophylaxis (consider resistance)
  • Persistent profound neutropenia

Assessment

Differential diagnosis

  • Bacterial pneumonia
  • Mucormycosis
  • Pulmonary embolism/infarct
  • Other invasive mould or PCP
  • Malignancy/haemorrhage

Investigations

  • CT chest (nodules with halo sign, cavitation, air-crescent)
  • Serum and bronchoalveolar lavage galactomannan
  • BAL fungal culture and microscopy
  • Beta-D-glucan (non-specific)
  • Aspergillus PCR where available
  • Assess net state of immunosuppression / neutrophil count

Management

  • Suspect in prolonged neutropenia or heavy immunosuppression with fever/pulmonary signs
  • Obtain CT chest early (halo sign is an early clue)
  • Send serum galactomannan and arrange bronchoscopy with BAL galactomannan/culture
  • Start antifungal therapy promptly in probable/proven disease
  • Choose voriconazole or isavuconazole first line
  • Reduce immunosuppression and support neutrophil recovery where possible
  • Perform therapeutic drug monitoring for voriconazole
  • Consider surgery for localised lesions near great vessels or massive haemoptysis
  • Monitor response with repeat imaging and galactomannan trend
  • Manage drug interactions (azoles are potent CYP inhibitors)
  • Continue therapy for a prolonged course guided by response and immune recovery
  • Give secondary prophylaxis if immunosuppression continues

Drugs & doses

Voriconazole 6 mg/kg IV every 12 h for 2 doses then 4 mg/kg every 12 h (target trough 1-5.5 mg/L)
Isavuconazole 200 mg (loading every 8 h for 6 doses) then 200 mg once daily
Liposomal amphotericin B 3-5 mg/kg IV daily (alternative/intolerance)
Posaconazole (salvage or where resistance/intolerance) with level monitoring

Disposition

Admit (critical); haematology/ID; consider thoracic surgery for complications.

Complications & pitfalls

  • Pulmonary haemorrhage/haemoptysis
  • Dissemination to brain and other organs
  • Respiratory failure
  • Azole toxicity and drug interactions
  • High mortality

Exam pearls

  • The CT halo sign is an early, time-sensitive diagnostic clue - act on it
  • Voriconazole needs therapeutic drug monitoring; levels vary widely
  • Distinguish from mucormycosis - voriconazole does not cover mucorales
  • Galactomannan from BAL is more sensitive than serum in non-neutropenic patients
  • Reversing immunosuppression/neutropenia is as important as antifungals

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.